CRISPRoff vs dCas9-TET vs dCas9-p300: Practical Comparison

Catalogues of epigenome editors list a dozen effectors. In practice, three dominate project design: CRISPRoff for durable silencing, dCas9-TET1 for removing methylation, and dCas9-p300 for depositing acetylation. They are often discussed as interchangeable "epigenetic switches", which is misleading — they act on different substrates, on different timescales, with different durability, and they support different conclusions.

This article compares them along the axes that determine experimental design: what they physically change, how fast, how long it lasts, what readout proves it worked, and which claims each one can and cannot support. The underlying mark biology and the general validation chain are covered in our pillar on DNA methylation, histone marks and chromatin state; here the focus is the three-way decision.

The important asymmetry: CRISPRoff writes a new mark that a maintenance system can propagate; TET removes an existing mark and depends on replication or active repair to make the loss permanent; p300 adds a mark that is rapidly removed by HDACs unless transcription reinforces it.

The three editors do not operate on the same clock.

• • p300 fusions can raise local acetylation within hours, and expression changes are often detectable within a day. Effects are also the most transient: withdraw the editor and HDACs restore the prior state quickly.
• • CRISPRoff represses transcription quickly through KRAB, but the methylation that makes silencing heritable accumulates over days. A day-2 experiment measures repression; a day-20 experiment measures something closer to memory.
• • TET1 fusions oxidize 5mC rapidly, but measurable demethylation at a CpG island typically requires days and successive divisions, and rarely reaches completion.

Practical implication: an experiment read at 48 hours will conclude that methylation-based tools "do not work" and that acetylation-based tools work well — a conclusion about kinetics, not about mechanism. Match the readout timepoint to the mark's turnover, and state the timepoint in the methods.

The distinction that matters operationally: p300 and TET are hypothesis-testing tools; CRISPRoff is a model-building tool. Projects that use a transient editor to build a long-term screening line usually discover the problem at the first passage check.

Durability is also not binary. A CRISPRoff line can be strongly silenced at passage 5 and partially reactivated at passage 20, particularly if the targeted CpGs are poorly methylated to begin with. The measurement of durability is therefore part of the experiment, not a validation afterthought — our companion piece on how long epigenetic silencing lasts sets out the design.

Two design habits prevent most of these: include the catalytically dead effector for the same guide, and report the fraction of alleles or CpGs actually modified rather than a binary edited/unedited statement.

Use CRISPRoff when: you need a stable, near-complete silencing for a screening line or a disease model, and you can wait one to three weeks for methylation to establish; or when you want silencing without a permanent DNA edit.

Use dCas9–TET1 when: the question is whether existing methylation is required for silencing at a specific locus, and you are prepared to quantify partial demethylation rather than expect a switch.

Use dCas9–p300 when: the question is whether an element or promoter is sufficient to drive expression when activated, and you want a chromatin-level rather than an activator-level answer; often best paired with CRISPRa at the same site to separate chromatin state from activator recruitment.

Combine them when: you want a causal loop. Silencing with CRISPRoff, then reversing it with TET1 at the same locus, is the cleanest available demonstration that the phenotype is methylation-dependent rather than a clone artifact.

The first row is the most instructive: CRISPRoff's durability comes from methylation, so a clone that is silent but unmethylated will not stay silent. Checking CpG methylation early saves a failed model.

EDITGENE builds all three configurations — CRISPRoff lines with methylation mapping, inducible dCas9–TET1 for demethylation studies, and dCas9–p300 lines for element activation — each with effector-recruitment data, mark-level readouts, and passage-stability documentation.

Tell us the locus and the claim you need to support. Contact EDITGENE to request a project consultation or quote.

Performance figures and timelines described here are indicative; editing efficiency, spreading, and durability vary by locus, cell type, effector configuration, and delivery method.

Mark-level changes do not establish function. Causal claims require catalytically dead controls, allele-resolved measurements, and functional readouts with neighbour controls.

• • Nuñez JK, et al. Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing. Cell. 2021;184:2503–2519.
• • Liu XS, et al. Editing DNA methylation in the mammalian genome. Cell. 2016;167:233–247.
• • Hilton IB, et al. Epigenome editing by a CRISPR-Cas9-based acetyltransferase activates genes from promoters and enhancers. Nature Biotechnology. 2015;33:510–517.
• • Amabile A, et al. Inheritable silencing of endogenous genes by hit-and-run targeted epigenetic editing. Cell. 2016;167:219–232.
• • Nakamura M, et al. CRISPR technologies for precise epigenome editing. Nature Cell Biology. 2021;23:11–22.